Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

Ana Alfonso, Guillermo Montalban-Bravo, Koichi Takahashi, Elias J. Jabbour, Tapan Kadia, Farhad Ravandi, Jorge Cortes, Zeev Estrov, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Carlos Bueso-Ramos, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticle

Abstract

Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n = 151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15%) were low-risk, 45 (39%) intermediate-1 risk, 42 (36%) intermediate-2, and 12 (10%) high-risk. 35 (23%) patients received single agent azacitidine, 73 (48%) single agent decitabine, and 43 (29%) combinations. With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR). Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17). By multivariate analysis, age < 70 years, higher levels of hemoglobin, absence of blast in peripheral blood and lower CPSS cytogenetic risk predicted for better OS. CR was significantly higher in those patients treated with decitabine (58.3%) when compared with azacitidine (20.6%) (P <.001). 13 patients (9%) received allo-SCT after a median of 4 cycles of HMA. 66 patients (50%) had HMA failure: 26 primary (34%) and 50 secondary (66%), including 35 (46%) that transformed to AML. Outcomes after HMA failure were poor with OS of 7 months (95%CI: 3-12). In conclusion, HMA are effective in CMML but new agents and combinations are needed. This data could be a benchmark for further drug development in CMML.

Original languageEnglish (US)
Pages (from-to)599-606
Number of pages8
JournalAmerican Journal of Hematology
Volume92
Issue number7
DOIs
StatePublished - Jul 2017
Externally publishedYes

Fingerprint

Leukemia, Myelomonocytic, Chronic
decitabine
Azacitidine
Survival
Benchmarking
Cytogenetics
Disease-Free Survival
Hemoglobins
Multivariate Analysis
Clinical Trials

ASJC Scopus subject areas

  • Hematology

Cite this

Alfonso, A., Montalban-Bravo, G., Takahashi, K., Jabbour, E. J., Kadia, T., Ravandi, F., ... Garcia-Manero, G. (2017). Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology, 92(7), 599-606. https://doi.org/10.1002/ajh.24735

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. / Alfonso, Ana; Montalban-Bravo, Guillermo; Takahashi, Koichi; Jabbour, Elias J.; Kadia, Tapan; Ravandi, Farhad; Cortes, Jorge; Estrov, Zeev; Borthakur, Gautam; Pemmaraju, Naveen; Konopleva, Marina; Bueso-Ramos, Carlos; Pierce, Sherry; Kantarjian, Hagop; Garcia-Manero, Guillermo.

In: American Journal of Hematology, Vol. 92, No. 7, 07.2017, p. 599-606.

Research output: Contribution to journalArticle

Alfonso, A, Montalban-Bravo, G, Takahashi, K, Jabbour, EJ, Kadia, T, Ravandi, F, Cortes, J, Estrov, Z, Borthakur, G, Pemmaraju, N, Konopleva, M, Bueso-Ramos, C, Pierce, S, Kantarjian, H & Garcia-Manero, G 2017, 'Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents', American Journal of Hematology, vol. 92, no. 7, pp. 599-606. https://doi.org/10.1002/ajh.24735
Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology. 2017 Jul;92(7):599-606. https://doi.org/10.1002/ajh.24735
Alfonso, Ana ; Montalban-Bravo, Guillermo ; Takahashi, Koichi ; Jabbour, Elias J. ; Kadia, Tapan ; Ravandi, Farhad ; Cortes, Jorge ; Estrov, Zeev ; Borthakur, Gautam ; Pemmaraju, Naveen ; Konopleva, Marina ; Bueso-Ramos, Carlos ; Pierce, Sherry ; Kantarjian, Hagop ; Garcia-Manero, Guillermo. / Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. In: American Journal of Hematology. 2017 ; Vol. 92, No. 7. pp. 599-606.
@article{26bd16a8eb404d4383e146635d88a293,
title = "Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents",
abstract = "Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n = 151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15{\%}) were low-risk, 45 (39{\%}) intermediate-1 risk, 42 (36{\%}) intermediate-2, and 12 (10{\%}) high-risk. 35 (23{\%}) patients received single agent azacitidine, 73 (48{\%}) single agent decitabine, and 43 (29{\%}) combinations. With a median follow-up of 17 months, overall response rate (ORR) was 75{\%}, with 41{\%} achieving complete response (CR). Median overall survival (OS) was 24 months (95{\%}CI: 20-28) and event-free survival 14 months (95{\%}CI: 11-17). By multivariate analysis, age < 70 years, higher levels of hemoglobin, absence of blast in peripheral blood and lower CPSS cytogenetic risk predicted for better OS. CR was significantly higher in those patients treated with decitabine (58.3{\%}) when compared with azacitidine (20.6{\%}) (P <.001). 13 patients (9{\%}) received allo-SCT after a median of 4 cycles of HMA. 66 patients (50{\%}) had HMA failure: 26 primary (34{\%}) and 50 secondary (66{\%}), including 35 (46{\%}) that transformed to AML. Outcomes after HMA failure were poor with OS of 7 months (95{\%}CI: 3-12). In conclusion, HMA are effective in CMML but new agents and combinations are needed. This data could be a benchmark for further drug development in CMML.",
author = "Ana Alfonso and Guillermo Montalban-Bravo and Koichi Takahashi and Jabbour, {Elias J.} and Tapan Kadia and Farhad Ravandi and Jorge Cortes and Zeev Estrov and Gautam Borthakur and Naveen Pemmaraju and Marina Konopleva and Carlos Bueso-Ramos and Sherry Pierce and Hagop Kantarjian and Guillermo Garcia-Manero",
year = "2017",
month = "7",
doi = "10.1002/ajh.24735",
language = "English (US)",
volume = "92",
pages = "599--606",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

AU - Alfonso, Ana

AU - Montalban-Bravo, Guillermo

AU - Takahashi, Koichi

AU - Jabbour, Elias J.

AU - Kadia, Tapan

AU - Ravandi, Farhad

AU - Cortes, Jorge

AU - Estrov, Zeev

AU - Borthakur, Gautam

AU - Pemmaraju, Naveen

AU - Konopleva, Marina

AU - Bueso-Ramos, Carlos

AU - Pierce, Sherry

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

PY - 2017/7

Y1 - 2017/7

N2 - Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n = 151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15%) were low-risk, 45 (39%) intermediate-1 risk, 42 (36%) intermediate-2, and 12 (10%) high-risk. 35 (23%) patients received single agent azacitidine, 73 (48%) single agent decitabine, and 43 (29%) combinations. With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR). Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17). By multivariate analysis, age < 70 years, higher levels of hemoglobin, absence of blast in peripheral blood and lower CPSS cytogenetic risk predicted for better OS. CR was significantly higher in those patients treated with decitabine (58.3%) when compared with azacitidine (20.6%) (P <.001). 13 patients (9%) received allo-SCT after a median of 4 cycles of HMA. 66 patients (50%) had HMA failure: 26 primary (34%) and 50 secondary (66%), including 35 (46%) that transformed to AML. Outcomes after HMA failure were poor with OS of 7 months (95%CI: 3-12). In conclusion, HMA are effective in CMML but new agents and combinations are needed. This data could be a benchmark for further drug development in CMML.

AB - Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n = 151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15%) were low-risk, 45 (39%) intermediate-1 risk, 42 (36%) intermediate-2, and 12 (10%) high-risk. 35 (23%) patients received single agent azacitidine, 73 (48%) single agent decitabine, and 43 (29%) combinations. With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR). Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17). By multivariate analysis, age < 70 years, higher levels of hemoglobin, absence of blast in peripheral blood and lower CPSS cytogenetic risk predicted for better OS. CR was significantly higher in those patients treated with decitabine (58.3%) when compared with azacitidine (20.6%) (P <.001). 13 patients (9%) received allo-SCT after a median of 4 cycles of HMA. 66 patients (50%) had HMA failure: 26 primary (34%) and 50 secondary (66%), including 35 (46%) that transformed to AML. Outcomes after HMA failure were poor with OS of 7 months (95%CI: 3-12). In conclusion, HMA are effective in CMML but new agents and combinations are needed. This data could be a benchmark for further drug development in CMML.

UR - http://www.scopus.com/inward/record.url?scp=85019314016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019314016&partnerID=8YFLogxK

U2 - 10.1002/ajh.24735

DO - 10.1002/ajh.24735

M3 - Article

C2 - 28370097

AN - SCOPUS:85019314016

VL - 92

SP - 599

EP - 606

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -